| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives
Discussions underway to expand adoption of ChemoFx in the U.S. and accelerate initial launch in Europe
PITTSBURGH, July 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today issued the following shareholder update:
To my fellow Shareholders,
The past several weeks have been particularly noteworthy and productive at Predictive Oncology, and I wanted to take this opportunity to provide a brief recap of recent developments.
Preparing for aggressive market expansion of ChemoFx® in the U.S. and de novo Launch in Europe
I'd like to begin with ChemoFx, which is our proprietary live-cell tumor profiling assay that uses a patient's own cells to measure chemotherapy responses in vitro, providing personalized guidance for treatment selection. By testing multiple chemotherapies on a patients' cancer cells before treatment selection, ChemoFx helps determine which chemotherapies are more likely to be effective on the tumor and which are less likely to provide benefit to the patient. With these data in-hand, oncologists can make better and faster treatment decisions – eliminating the current "trial-and-error" approach – which could go a long way towards improving patient outcomes while saving precious time and money.
This flagship assay, which stands as a renewable and extensible asset for the Company, was the primary assay by which the Company acquired more than 150,000 tumor samples, analyzed more than twenty-five years of drug response data and represents a significant opportunity for the Company to steadily augment the biobank, consistently develop novel drug response data and increase the likelihood of recurring revenue. The groundwork to expand availability of ChemoFx in the U.S is already underway, including meaningful and productive discussions with potential channel partners, and other end-users, including R&D-based pharmaceutical manufacturers.
As we look to develop the next generation of ChemoFx, the Company anticipates the ability to extend beyond gynecological cancers, into other tumor types, including breast, colon and lung.
More importantly, the ability to obtain a patient tumor sample and monitor its growth and drug response as it transitions from a 2D cell culture to cryopreservation and then to 3D cell spheroids exemplifies the relevance and availability of our samples for high-throughput drug discovery, personalized medicine, and biomarker discovery. The utilization of cryopreserved dissociated tumor cells (DTCs) represents a scalable resource for research and clinical trials with viable primary tumor material.
The high throughput screening [HTS] market is projected to reach $69.5 billion by 2032, reflecting a CAGR of 12.18%, according to SNS Insider research. There is a growing adoption of 3D cell cultures which provide more physiologically relevant models for screening, enhancing the predictive power of HTS assays.
Collectively, these capabilities directly support the Company's AI-driven drug discovery initiatives by generating high-quality data that feeds into predictive models and supports biomarker discovery, companion diagnostics, and clinical trial design.
Posted In: POAI
